Table S1.
Multivariate analysis of overall survival after stratification by ER status
| Variable | ER positive
|
ER negative/borderline
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age (years) | ||||
| <50 | Reference | Reference | ||
| >50 | 4.29 (3.38–5.43) | <0.001 | 2.73 (1.72–4.35) | <0.001 |
| Year of diagnosis | ||||
| 1998–2002 | Reference | Reference | ||
| 2003–2007 | 0.84 (0.70–1.01) | 0.069 | 0.76 (0.53–1.09) | 0.137 |
| Race | ||||
| Black | Reference | Reference | ||
| White | 0.75 (0.62–0.91) | 0.003 | 0.81 (0.43–1.54) | 0.317 |
| Other* | 0.55 (0.40–0.76) | <0.001 | 0.80 (0.52–1.24) | 0.519 |
| Marital status | ||||
| Non-married† | Reference | Reference | ||
| Married | 0.55 (0.48–0.62) | <0.001 | 0.60 (0.45–0.79) | <0.001 |
| Poverty–high school index | ||||
| Low SEP | Reference | Reference | ||
| Middle SEP | 1.10 (0.93–1.30) | 0.278 | 1.35 (0.94–1.92) | 0.101 |
| High SEP | 0.93 (0.76–1.12) | 0.435 | 0.89 (0.58–1.36) | 0.576 |
| Laterality | ||||
| Left | Reference | Reference | ||
| Right | 1.03 (0.91–1.18) | 0.645 | 0.98 (0.74–1.29) | 0.871 |
| Primary site | ||||
| Single-quadrant lesions | Reference | Reference | ||
| Multi-quadrant lesions | 1.16 (0.97–1.40) | 0.114 | 1.43 (1.00–2.04) | 0.047 |
| PR status | ||||
| Negative/borderline | Reference | Reference | ||
| Positive | 0.81 (0.68–0.96) | 0.013 | 1.33 (0.82–2.17) | 0.250 |
| Grade | ||||
| I | Reference | Reference | ||
| II | 0.98 (0.82–1.18) | 0.836 | 1.15 (0.51–2.58) | 0.735 |
| III and IV | 0.97 (0.81–1.18) | 0.782 | 1.12 (0.52–2.40) | 0.776 |
| RT | ||||
| No | Reference | Reference | ||
| Yes | 0.61 (0.53–0.69) | <0.001 | 0.56 (0.42–0.75) | <0.001 |
Notes:
*
Including American Indian/Alaskan Native and Asian/Pacific Islander.
†
Including divorced, widowed, single (never married), and separated.
Abbreviations: ER, estrogen receptor; HR, hazard ratio; CI, confidence interval; SEP, socioeconomic position; PR, progesterone receptor; RT, radiotherapy.